🔗 Share this article

As the United States undertakes sweeping revisions to its vaccination recommendations, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who initially gained attention by casting doubt on COVID-19 vaccinations in the pandemic and has focused upon possible deaths following Covid immunization in her brief time at the FDA.

Scheduled Overhauls to Childhood Vaccine Program

Public health authorities were set to unveil radical changes to the childhood vaccine schedule earlier this month, bringing the US with Denmark’s immunization schedule, according to reports – a significant shift that would place the US out of alignment with many the world with no evidence for benefit. This reveal has been pushed back until the new year.

In place of the director of the vaccine center, Høeg is set to present at the event. She was just designated interim head of the FDA’s drug evaluation center, the fifth appointee to run the office this year.

A New Direction at the Agency

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and biologics divisions as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a greater focus upon rolling back previously authorized vaccines at the FDA.

Høeg has often pushed for discontinuing some pediatric vaccine recommendations in the US to become more in line with the Danish model, a country with comprehensive healthcare and a population approximately the population of Wisconsin’s.

So far public appearances, she has continued to focus on immunizations – usually the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Qualifications

Høeg has no apparent background in pharmaceutical research, regulation or management, which has been typical for former heads of the biologics center. She has worked at the FDA as a key advisor to the agency head and CBER since spring.

“It seems she lacks to have any of the qualifications” for running the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in leading a sizeable institution. She is not an expert in pharmaceutical oversight.”

Former heads of CBER would “grasp regulatory frameworks and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she lacks the sort of resume that prior appointees who ran CBER have had.”

This division has an vast workload at the agency, she emphasized.

“Many people just focuses on the innovative therapies, but the off-patent medication office approves a multitude of generic medications. There is also a biosimilars division, non-prescription drug unit and more, and every single one need to be managed,” she said. “The area you neglect, that is the part that I always told people is going to bite you.”

Furthermore, a substantial administrative element to the position, which oversees more than 5,000 employees. “It is a huge administrative position, if you execute it properly,” she concluded.

Official Statement and Disputed Policies

In response to concerns about Dr. Høeg's credentials and whether this selection represents more teamwork among regulatory chiefs on vaccines, a spokesperson said that the “questions rely on inaccurate assumptions”.

“This background matches the duties of her position,” the spokesperson said, pointing to the months Høeg spent counseling the agency head on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg takes over the agency head's recently launched expedited review system, a disputed expedited drug-approval program that reportedly concerned her former heads. “How are these medications being selected for this voucher program? Who is making the decisions?” Dr. Howard asked. “There is a lot of confidentiality happening at the agency right now.”

In general, he remarked, “the FDA appears to be shifting towards more relaxed rules of pharmaceuticals, with the exception of immunizations.”

Documented History on Vaccines

Regarding vaccines, Dr. Høeg has a clearer, if problematic, past, Howard have noted. She released a research paper using unverified volunteer-provided data to determine the frequency of myocarditis following COVID-19 vaccination. She advised the Florida top health official Dr. Joseph Ladapo, who was said to have modified findings to imply Covid vaccines are riskier than they are.

Part of her “desired changes” for the incoming administration featured altering guidelines for recently developed shots and ending “optional” vaccines, she said after the election on a audio program. At the agency, Høeg has reportedly floated the idea of excluding young men from getting COVID-19 vaccines.

“She’s an complete ideologue who commences with her beliefs and reverse-engineers to accommodate the evidence in a highly deceptive, fraudulent fashion,” Howard said.

Gaining Influence and a “Push for Payback”

Høeg joined other skeptics, {like|